Oxford BioDynamics (LON:OBD) Stock Price Down 0.5% – What’s Next?

Oxford BioDynamics Plc (LON:OBD)’s stock price traded down 0.5% during mid-day trading on Tuesday . The stock traded as low as GBX 0.40 ($0.01) and last traded at GBX 0.40 ($0.01). 1,056,289 shares changed hands during mid-day trading, a decline of 94% from the average session volume of 17,376,854 shares. The stock had previously closed at GBX 0.40 ($0.01).

Analyst Ratings Changes

Separately, Shore Capital reiterated a “house stock” rating on shares of Oxford BioDynamics in a research report on Thursday, March 13th.

Oxford BioDynamics Price Performance

The company has a 50-day moving average of GBX 0.40 and a two-hundred day moving average of GBX 0.63. The stock has a market capitalization of £7.48 million, a PE ratio of -0.07 and a beta of 0.42. The company has a debt-to-equity ratio of 370.22, a current ratio of 0.68 and a quick ratio of 2.80.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.